0001209191-18-003253.txt : 20180111 0001209191-18-003253.hdr.sgml : 20180111 20180111162118 ACCESSION NUMBER: 0001209191-18-003253 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180109 FILED AS OF DATE: 20180111 DATE AS OF CHANGE: 20180111 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dumas Jacques CENTRAL INDEX KEY: 0001598640 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35837 FILM NUMBER: 18523844 MAIL ADDRESS: STREET 1: C/O IDENIX PHARMACEUTICALS, INC. STREET 2: 320 BENT STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TETRAPHASE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001373707 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 480 ARSENAL STREET STREET 2: SUITE 110 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617.715.3600 MAIL ADDRESS: STREET 1: 480 ARSENAL STREET STREET 2: SUITE 110 CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-01-09 0 0001373707 TETRAPHASE PHARMACEUTICALS INC TTPH 0001598640 Dumas Jacques C/O TETRAPHASE PHARMACEUTICALS, INC. 480 ARSENAL STREET WATERTOWN MA 02472 0 1 0 0 Chief ScientificOfficer Common Stock 2018-01-09 4 S 0 7167 6.21 D 0 D On January 6, 2016, the Reporting person was granted 35,000 restricted stock units ("RSUs")( the "2016 RSU grant") that were previously reported on Table II Of Form 4, which form was filed with the Securities and Exchange Commission on June 10, 2016. Of the 2016 RSU grant, 11,667 shares vested on January 6, 2018 of which 4,500 shares were withheld by the Issuer to satisfy the reporting person's tax withholding obligations in connection with the delivery of the conversion of the RSUs into common stock on the vesting date. The remaining 7,167 shares were sold on January 9, 2018 and such sale is reported on this Form 4. The sale of these shares of common stock reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 16, 2017. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $6.14 to $6.31 per share. The reporting person undertakes to provide, upon request, to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. /s/Maria Stahl as Attorney-in-Fact for Jacques Dumas 2018-01-11